CN Patent

CN114105957B — 奥希替尼-对苯二甲酸晶体及其制备方法

Assigned to Lunan Pharmaceutical Group Corp · Expires 2025-07-18 · 1y expired

What this patent protects

本发明提供了具有优异理化性质的奥希替尼‑对苯二甲酸晶体A和奥希替尼‑对苯二甲酸晶体B。所述的晶体A使用Cu‑Kα辐射,以2θ表示的X射线衍射谱图至少在5.72±0.2°,6.10±0.2°,10.23±0.2°,12.24±0.2°,21.80±0.2°,23.00±0.2°,26.22±0.2°有特征峰;所述的晶体B使用Cu‑Kα辐射,以2θ表示的X射线衍射谱图至少在5.59±0.2°,6.32±0.2°,10.54±0.2°,11.14±0.2°,16.68±0.2°,18.67±0.2°,25.07±0.2°有特征峰。本发明所述晶体可以有效的改善奥…

USPTO Abstract

本发明提供了具有优异理化性质的奥希替尼‑对苯二甲酸晶体A和奥希替尼‑对苯二甲酸晶体B。所述的晶体A使用Cu‑Kα辐射,以2θ表示的X射线衍射谱图至少在5.72±0.2°,6.10±0.2°,10.23±0.2°,12.24±0.2°,21.80±0.2°,23.00±0.2°,26.22±0.2°有特征峰;所述的晶体B使用Cu‑Kα辐射,以2θ表示的X射线衍射谱图至少在5.59±0.2°,6.32±0.2°,10.54±0.2°,11.14±0.2°,16.68±0.2°,18.67±0.2°,25.07±0.2°有特征峰。本发明所述晶体可以有效的改善奥希替尼溶解度低、高引湿性和易潮解的弊端;并且所述的晶体制备方法简单、操作方便。

Drugs covered by this patent

Patent Metadata

Patent number
CN114105957B
Jurisdiction
CN
Classification
Expires
2025-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Lunan Pharmaceutical Group Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.